Persistence Capital Partners supports Warnex's merger with Diagnos
Life sciences research company Warnex Inc (TSXV: WNX.H) has agreed to merge with a wholly-owned subsidiary of Diagnos Inc (TSXV: ADK). Warnex's majority investor, Canadian healthcare-focused private equity firm Persistence Capital Partners, has indicated that it will support the deal, which when closed is expected to see security-holders of Warnex with around 27.96% of the issued and outstanding shares of Diagnos, and the shareholders of Diagnos with around 72.04% of the issued and outstanding shares. Persistence achieved a partial exit from the Laval, Québec-based Warnex in December 2012.
6 May 2014•4 mins read
